Details of the Drug Combination

General Information of Drug Combination (ID: DCLP92R)

• Drug Combination Name: NITD609 + Azelnidipine
• Indication: DD2; Status: Investigative [1]
• Component Drugs:
  NITD609 (DMQHBSX): Small molecular drug
  Azelnidipine (DMA12HL): N.A.
• High-throughput Screening Result:
  Testing Cell Line: DD2
  Zero Interaction Potency (ZIP) Score: 17.247
  Bliss Independence Score: 5.677
  Loewe Additivity Score: 20.221
  LHighest Single Agent (HSA) Score: 1.431

Molecular Interaction Atlas of This Drug Combination

Indication(s) of NITD609

Disease Entry	ICD 11	Status	REF
Malaria	1F40-1F45	Phase 2	[2]

NITD609 Interacts with 2 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Voltage-gated potassium channel Kv11.1 (KCNH2)	TTQ6VDM	KCNH2_HUMAN	Inhibitor	[4]
Adenosine A3 receptor (ADORA3)	TTJFY5U	AA3R_HUMAN	Inhibitor	[4]

Indication(s) of Azelnidipine

Disease Entry	ICD 11	Status	REF
Hypertension	BA00-BA04	Approved	[3]

Azelnidipine Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[5]

Test Results of This Drug Combination in Other Disease Systems

Indication	DrugCom ID	Cell Line	Status	REF
Hepatoblastoma	DC5D37D	HB3	Investigative	[6]

References

• [1] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
• [2] ClinicalTrials.gov (NCT01836458) A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection. U.S. National Institutes of Health.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010 Sep 3;329(5996):1175-80.
• [5] KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017 Jan 4;45(D1):D353-D361. (DRUG:D01145)
• [6] CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976